| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥40.1B | ¥40.6B | -1.3% |
| Operating Income | ¥0.5B | ¥0.8B | -32.9% |
| Ordinary Income | ¥0.8B | ¥1.1B | -22.0% |
| Net Income | ¥0.7B | ¥0.8B | -12.4% |
| ROE | 2.2% | 2.6% | - |
FY2026 Q2 results showed revenue of 40.1B yen (YoY -1.3%), operating income of 0.5B yen (YoY -32.9%), ordinary income of 0.8B yen (YoY -22.0%), and net income of 0.7B yen (YoY -12.4%). The company maintained near-flat revenue but experienced significant profit margin compression, with operating margin declining to 1.3% from approximately 2.0% in the prior year period. The deterioration was driven by SG&A expenses of 12.3B yen consuming nearly all of the gross profit of 12.8B yen, while operating cash flow turned negative at -0.8B yen despite positive net income, indicating serious cash conversion challenges stemming from working capital expansion.
Revenue remained essentially flat at 40.1B yen (YoY -1.3%), suggesting stable underlying demand in the medical and nursing care electric bed market. The minimal top-line movement reflects the mature nature of the single-segment business and likely indicates steady replacement demand without major market expansion. On the profit side, gross profit of 12.8B yen maintained a 32.0% margin, but SG&A expenses of 12.3B yen (representing 30.6% of revenue) left minimal operating margin. The 32.9% decline in operating income from 0.8B yen to 0.5B yen was primarily driven by SG&A expense growth outpacing the modest revenue decline, indicating negative operating leverage. The gap between operating income of 0.5B yen and ordinary income of 0.8B yen of approximately 0.3B yen was attributable to equity method gains of 0.3B yen, which provided a non-core earnings contribution. Net income of 0.7B yen remained relatively close to ordinary income with minimal extraordinary items, though the 12.4% YoY decline was less severe than the operating income decline due to the non-operating income buffer. This represents a "revenue flat, profit down" pattern where stable revenue could not offset fixed cost pressures and resulted in margin compression across all profit levels.
[Profitability] ROE of 2.2% reflects weak equity returns, with net profit margin of 1.7% and operating margin of 1.3% indicating extremely thin profitability on sales. The low operating margin resulted from SG&A expenses consuming 96% of gross profit. Return on assets stood at 2.1%, while return on invested capital was 1.4%, both indicating poor capital efficiency. EBIT interest coverage of approximately 4.1x provides basic debt service coverage but with limited buffer. [Cash Quality] Cash and deposits of 15.7B yen provide coverage of 0.83x against short-term debt of 8.0B yen, supplemented by investment securities of 14.0B yen. Operating cash flow of -0.8B yen turned negative despite positive net income, with operating CF to net income ratio of -1.23x indicating poor earnings quality. Cash conversion ratio of -0.73x confirms weak cash realization. [Investment Efficiency] Total asset turnover of 0.61x reflects moderate asset utilization, though inventory turnover deteriorated with finished goods inventory increasing 25.3% YoY to 8.3B yen. Receivables of 12.0B yen also increased, extending the working capital cycle. [Financial Health] Equity ratio of 48.8% indicates moderate financial stability. Current ratio of 224.0% appears healthy on the surface. However, interest-bearing debt of 16.7B yen (short-term 8.0B yen, long-term 8.7B yen) against EBITDA of approximately 1.2B yen results in net debt to EBITDA of approximately 14.4x, representing elevated leverage. The debt-to-equity ratio of 1.05x and short-term debt ratio of 48% raise refinancing risk concerns.
Operating cash flow of -0.8B yen contrasts sharply with net income of 0.7B yen, driven by working capital deterioration that consumed 1.5B yen more cash than the prior year period. The subtotal before working capital changes was -0.4B yen, already weak due to low profitability, then inventory increases of 1.4B yen and receivables increases of 0.8B yen further drained cash, partially offset by payables increases of 0.7B yen. Income taxes paid of 0.4B yen and interest paid of 0.1B yen represented additional outflows. Investing cash flow of -1.9B yen included capital expenditures of 0.5B yen, which represented 0.85x of depreciation and amortization of 0.6B yen, indicating maintenance-level investment. Financing cash flow of positive 1.1B yen likely reflected new borrowings or refinancing activities to fund the negative free cash flow. Free cash flow of -2.8B yen indicates the company consumed cash significantly beyond its earnings generation, requiring external financing. The severely negative FCF combined with high dividend expectations raises sustainability concerns regarding the capital allocation strategy.
Ordinary income of 0.8B yen compared to operating income of 0.5B yen reflects a net non-operating contribution of approximately 0.3B yen, representing 0.8% of revenue. This non-operating income consists primarily of equity method gains of 0.3B yen, which constitutes a recurring but non-core earnings source from associated company investments. Non-operating expenses of 0.1B yen included interest expense of 0.1B yen and foreign exchange losses of 0.1B yen, offsetting modest other non-operating income of 0.1B yen. The reliance on equity method income for nearly 38% of ordinary income raises concerns about core business profitability. Most critically, operating cash flow was negative at -0.8B yen while net income was positive at 0.7B yen, indicating poor earnings quality due to significant accruals. The accrual ratio of 2.3% and the substantial working capital build in inventories and receivables suggest earnings are not converting to cash, which is a material red flag for earnings sustainability.
Progress against full-year guidance shows revenue at 45.6% (40.1B yen actual vs 88.0B yen forecast), operating income at 13.5% (0.5B yen vs 4.0B yen forecast), and ordinary income at 19.5% (0.8B yen vs 4.2B yen forecast) of full-year targets. At the midpoint of the fiscal year, these progress rates are significantly below the standard 50% benchmark, particularly for operating income which is 36.5 percentage points behind. This substantial shortfall indicates either significant back-half weighting in the company's business model or heightened risk to achieving full-year guidance. The company anticipates operating income to improve dramatically to 4.0B yen for the full year (representing 118.0% YoY growth), implying second-half operating income would need to reach approximately 3.5B yen compared to first-half of 0.5B yen, a seven-fold increase. Such backend loading appears aggressive given current profitability trends and negative operating cash flow. The forecast assumes substantial margin recovery through either volume leverage or cost reductions that have not yet materialized in Q2 results.
The company plans an annual dividend of 24.00 yen per share for the full fiscal year, with no interim dividend in Q2 and an anticipated year-end dividend of 18.00 yen based on historical patterns. Against forecasted EPS of 77.96 yen, this represents a payout ratio of 30.8% based on full-year earnings projections. However, using Q2 actual EPS of 20.65 yen annualized, the implied payout ratio would be approximately 58%. More concerning, actual net income for Q2 of 0.7B yen annualized suggests total dividend payments of approximately 0.9B yen (24 yen times 3,726 thousand shares outstanding less treasury shares), implying a payout ratio approaching 97% if current earnings run-rate persists. Given free cash flow of -2.8B yen in Q2, the dividend would require drawing on cash reserves or additional financing. The company's cash position of 15.7B yen provides near-term coverage, but the combination of negative FCF and high payout raises sustainability concerns unless second-half profitability and cash generation improve substantially as guided.
Single-segment concentration risk represents the primary business risk, as the company operates exclusively in medical and nursing care electric beds with no revenue diversification. This exposes the company to sector-specific headwinds including changes in healthcare reimbursement policies, government subsidy programs, and demographic shifts affecting institutional purchasing patterns. Working capital management deterioration poses significant operational risk, evidenced by inventory increases of 1.7B yen (25.3% YoY growth) and receivables expansion, extending cash conversion cycles to approximately 281 days (112 days inventory + 105 days receivables - 129 days payables estimated from industry benchmarks). This working capital intensity consumes cash and increases vulnerability to demand shocks or collection issues. Financial leverage and refinancing risk warrant close monitoring, with net debt to EBITDA of 14.4x representing extremely high leverage and short-term debt of 8.0B yen (48% of total debt) creating near-term refinancing requirements. Combined with negative operating cash flow, the company faces potential liquidity stress if unable to roll over short-term facilities or if lending conditions tighten, particularly given interest coverage of only 4.1x leaves limited margin for earnings deterioration.
[Industry Position] (Reference - Proprietary Analysis)
The company's profitability metrics fall significantly below manufacturing industry medians. Operating margin of 1.3% substantially trails the industry median of 8.8% (IQR: 3.0%-11.0%), positioning the company in the bottom quartile. Net profit margin of 1.7% similarly underperforms the industry median of 5.4% (IQR: 1.1%-8.2%). Return on equity of 2.2% ranks well below the industry median of 4.4% (IQR: 1.4%-8.7%), while ROA of 2.1% also lags the median of 1.9% but remains within the interquartile range.
Financial health metrics show mixed positioning. The equity ratio of 48.8% aligns closely with the industry median of 48.6% (IQR: 26.7%-65.2%), indicating comparable capital structure. However, net debt to EBITDA of 14.4x compares unfavorably to the industry median of 15.35x (IQR: 7.23-75.76), placing the company near the median but still in elevated leverage territory. The current ratio of 224.0% falls below the industry median of 274%, though remains within a reasonable range.
Operational efficiency reveals significant challenges. Cash conversion ratio of -0.73x starkly contrasts with the industry median of 0.91x (IQR: -1.33-1.19), indicating severe cash generation weakness. Asset turnover of 0.61x exceeds the industry median of 0.36x (IQR: 0.32-0.39), suggesting relatively better asset utilization despite profitability challenges. Inventory turnover of approximately 112 days significantly outperforms the industry median of 261 days (IQR: 170-368 days), representing a relative strength in inventory management despite recent increases. Revenue growth of -1.3% falls below the industry median of 11.7% (IQR: -5.4% to 28.3%), positioning the company in the lower half of growth performers.
(Industry: Manufacturing (7 companies), Comparison: FY2025 Q2, Source: Proprietary analysis)
Significant margin compression and cash conversion challenges represent the most critical earnings observations, with operating margin declining to 1.3% placing the company well below industry standards and negative operating cash flow of -0.8B yen despite positive net income indicating fundamental working capital management issues. The deterioration stems from SG&A expenses consuming 96% of gross profit while inventory and receivables expanded substantially, creating a 1.5B yen working capital drain. This pattern suggests either business model stress or operational execution issues requiring management intervention. The company's guidance implies dramatic second-half margin recovery to achieve full-year operating income of 4.0B yen, requiring approximately 3.5B yen in H2 versus 0.5B yen in H1, which appears aggressive absent clear evidence of seasonal patterns or concrete turnaround initiatives.
Elevated financial leverage combined with weak cash generation creates material refinancing and sustainability risks, particularly given net debt to EBITDA of 14.4x and short-term debt representing 48% of total borrowings. The planned dividend payout of 24 yen per share implies a payout ratio approaching 97% based on current earnings run rates and would require approximately 0.9B yen against negative free cash flow of -2.8B yen, necessitating either cash reserve drawdowns or additional external financing. While current cash holdings of 15.7B yen provide near-term buffer, the combination of negative FCF, high leverage, and elevated payout ratio is unsustainable without significant operational improvement. The investment securities position of 14.0B yen represents a potential liquidity source but utilizing non-operating assets for operating needs or dividends would further weaken the balance sheet structure and financial flexibility in this capital-intensive manufacturing business.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.